Search

Your search keyword '"Ueno, Miho"' showing total 8 results
Start Over Author "Ueno, Miho" Search Limiters Full Text
8 results on '"Ueno, Miho"'

2. Endometrioid Adenocarcinoma with High-Grade Transformation with Serous and Choriocarcinomatous Differentiation - A Case Report

Author

Senn Wakahashi, Tamotsu Sudo, Eriko Nakagawa, Sayaka Ueno, Miho Muraji, Seiji Kanayama, Hiroe Itami, Fumi Kawakami, Takashi Yamada, Satoshi Yamaguchi, Kiyoshi Fujiwara, Hironobu Nishikawa, Ryuichiro Nishimura, Chiho Ohbayashi

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

A choriocarcinoma component with a malignant tumor is relatively rare. We present a case of an 85-year-old woman with mixed carcinoma, which was endometrioid adenocarcinoma with squamous differentiation, choriocarcinoma and a disseminated peritoneal nodule, which was papillary serous adenocarcinoma. The patient received surgery and conservative treatment. Twenty weeks after surgery, a recurring tumor appeared at the Douglas pouch. Histology showed that the recurring tumor was poorly differentiated carcinoma that was very different from the primary tumor. This case represents an unusual uterine corpus cancer with high-grade transformation with serous and choriocarcinomatous differentiation. This case also demonstrates the capacity of tumor cells to differentiate into divergent elements.

Published
2012

4. Retrospective analysis of the efficacy and safety of eribulin therapy for metastatic breast cancer in daily practice

Author

Tanaka, Toshihiro, Ueno, Miho, Nakashima, Yuta, Chinen, Shotaro, Sato, Eiichi, Masaki, Michio, Mogi, Ai, Sasaki, Hidenori, Tamura, Kazuo, and Takamatsu, Yasushi

Subjects
Adult, post‐treatment therapy, Antineoplastic Agents, Breast Neoplasms, Original Articles, Ketones, Middle Aged, Disease-Free Survival, Drug Administration Schedule, clinical practice, Treatment Outcome, Chemotherapy, Humans, Original Article, Female, metastatic breast cancer, Neoplasm Metastasis, Furans, eribulin, Aged, Retrospective Studies
Abstract

Background Evidence of eribulin therapy for metastatic breast cancer (MBC) in clinical practice is not well documented. Methods We retrospectively analyzed the safety and efficacy of eribulin in 29 MBC patients from 2011 to 2016 at Fukuoka University Hospital. Results The median patient age, number of courses, total dose, and relative dose intensity were as follows: 65 years, five courses, 8.6 mg/m2, and 75%, respectively. One patient achieved a complete response, (CR) six a partial response (PR), eight stable disease (SD) and 14 patients exhibited progressive disease. The objective response rate (ORR: CR + PR) was 24.1%, and the clinical benefit rate (CBR: CR + PR + SD) was 51.7%. The median progression‐free survival was 90 days (95% confidence interval [CI] 67–126) and median overall survival was 264 days (95% CI 198–357). In patients who previously received 2–4 regimens, the ORR was 28.5% and the CBR was 57.1%. In patients who received 5–12 regimens, the ORR was 20% and the CBR was 45%. Chemotherapy was administered to 20 patients (69%) after eribulin administration, and the median overall survival rate of cases that achieved greater than a PR was 1088 days. The most frequent treatment‐related grade 3/4 adverse events were neutropenia (55.2%), and febrile neutropenia (20.1%). Grade 3 peripheral neuropathy occurred in 13.8% of patients, but was not exacerbated even if present before treatment. Conclusion Eribulin is effective for MBC patients who have received multiple chemotherapies. Neutropenia and febrile neutropenia may develop after heavy prior therapy.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results